vs
LIGAND PHARMACEUTICALS INC（LGND）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
LIGAND PHARMACEUTICALS INC的季度营收约是READING INTERNATIONAL INC的1.2倍（$59.7M vs $50.3M），LIGAND PHARMACEUTICALS INC净利率更高（75.1% vs -5.1%，领先80.2%），LIGAND PHARMACEUTICALS INC同比增速更快（39.4% vs -14.2%），LIGAND PHARMACEUTICALS INC自由现金流更多（$45.9M vs $4.1M），过去两年LIGAND PHARMACEUTICALS INC的营收复合增速更高（38.8% vs 5.6%）
利根制药是美国的生物制药企业，专注于收购和开发可产生特许权使用费的资产。截至2024年，公司的资产组合涵盖约90款覆盖多个治疗领域的药品的特许权使用权，可从多发性骨髓瘤治疗药物凯洛斯、Evomela，肾病治疗药物Filspari，以及肺炎球菌疫苗Vaxneuvance等知名产品中获得相关收益。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
LGND vs RDI — 直观对比
营收规模更大
LGND
是对方的1.2倍
$50.3M
营收增速更快
LGND
高出53.5%
-14.2%
净利率更高
LGND
高出80.2%
-5.1%
自由现金流更多
LGND
多$41.8M
$4.1M
两年增速更快
LGND
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $59.7M | $50.3M |
| 净利润 | $44.8M | $-2.6M |
| 毛利率 | — | — |
| 营业利润率 | 23.2% | -1.9% |
| 净利率 | 75.1% | -5.1% |
| 营收同比 | 39.4% | -14.2% |
| 净利润同比 | 244.1% | -14.5% |
| 每股收益（稀释后） | $2.42 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LGNDRDI
| Q4 25 | $59.7M | $50.3M | ||
| Q3 25 | $115.5M | $52.2M | ||
| Q2 25 | $47.6M | $60.4M | ||
| Q1 25 | $45.3M | $40.2M | ||
| Q4 24 | $42.8M | $58.6M | ||
| Q3 24 | $51.8M | $60.1M | ||
| Q2 24 | $41.5M | $46.8M | ||
| Q1 24 | $31.0M | $45.1M |
净利润LGNDRDI
| Q4 25 | $44.8M | $-2.6M | ||
| Q3 25 | $117.3M | $-4.2M | ||
| Q2 25 | $4.8M | $-2.7M | ||
| Q1 25 | $-42.5M | $-4.8M | ||
| Q4 24 | $-31.1M | $-2.2M | ||
| Q3 24 | $-7.2M | $-7.0M | ||
| Q2 24 | $-51.9M | $-12.8M | ||
| Q1 24 | $86.1M | $-13.2M |
营业利润率LGNDRDI
| Q4 25 | 23.2% | -1.9% | ||
| Q3 25 | 47.6% | -0.6% | ||
| Q2 25 | 17.7% | 4.8% | ||
| Q1 25 | -79.9% | -17.2% | ||
| Q4 24 | -22.5% | 2.6% | ||
| Q3 24 | 6.1% | -0.6% | ||
| Q2 24 | -46.0% | -16.4% | ||
| Q1 24 | 9.6% | -16.7% |
净利率LGNDRDI
| Q4 25 | 75.1% | -5.1% | ||
| Q3 25 | 101.6% | -8.0% | ||
| Q2 25 | 10.2% | -4.4% | ||
| Q1 25 | -93.6% | -11.8% | ||
| Q4 24 | -72.6% | -3.8% | ||
| Q3 24 | -13.8% | -11.7% | ||
| Q2 24 | -125.0% | -27.4% | ||
| Q1 24 | 278.1% | -29.4% |
每股收益（稀释后）LGNDRDI
| Q4 25 | $2.42 | $-0.11 | ||
| Q3 25 | $5.68 | $-0.18 | ||
| Q2 25 | $0.24 | $-0.12 | ||
| Q1 25 | $-2.21 | $-0.21 | ||
| Q4 24 | $-1.70 | $-0.11 | ||
| Q3 24 | $-0.39 | $-0.31 | ||
| Q2 24 | $-2.88 | $-0.57 | ||
| Q1 24 | $4.75 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $733.5M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $1.0B | $-18.2M |
| 总资产 | $1.6B | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LGNDRDI
| Q4 25 | $733.5M | $10.5M | ||
| Q3 25 | $664.5M | $8.1M | ||
| Q2 25 | $245.0M | $9.1M | ||
| Q1 25 | $208.9M | $5.9M | ||
| Q4 24 | $256.2M | $12.4M | ||
| Q3 24 | $219.6M | $10.1M | ||
| Q2 24 | $226.9M | $9.3M | ||
| Q1 24 | $310.6M | $7.5M |
总债务LGNDRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LGNDRDI
| Q4 25 | $1.0B | $-18.2M | ||
| Q3 25 | $950.2M | $-12.1M | ||
| Q2 25 | $828.5M | $-7.7M | ||
| Q1 25 | $795.5M | $-8.1M | ||
| Q4 24 | $830.4M | $-4.4M | ||
| Q3 24 | $841.2M | $1.6M | ||
| Q2 24 | $775.2M | $6.5M | ||
| Q1 24 | $806.5M | $18.0M |
总资产LGNDRDI
| Q4 25 | $1.6B | $434.9M | ||
| Q3 25 | $1.5B | $435.2M | ||
| Q2 25 | $948.6M | $438.1M | ||
| Q1 25 | $905.4M | $441.0M | ||
| Q4 24 | $941.8M | $471.0M | ||
| Q3 24 | $954.9M | $495.7M | ||
| Q2 24 | $866.4M | $494.9M | ||
| Q1 24 | $913.9M | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.9M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $45.9M | $4.1M |
| 自由现金流率自由现金流/营收 | 76.9% | 8.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.03× | — |
| 过去12个月自由现金流最近4个季度 | $48.9M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流LGNDRDI
| Q4 25 | $45.9M | $4.3M | ||
| Q3 25 | $13.1M | $295.0K | ||
| Q2 25 | $15.8M | $1.6M | ||
| Q1 25 | $-25.4M | $-7.7M | ||
| Q4 24 | $28.5M | $8.0M | ||
| Q3 24 | $36.5M | $1.3M | ||
| Q2 24 | $13.3M | $-10.4M | ||
| Q1 24 | $18.7M | $-2.8M |
自由现金流LGNDRDI
| Q4 25 | $45.9M | $4.1M | ||
| Q3 25 | $13.1M | $-246.0K | ||
| Q2 25 | $15.6M | $1.2M | ||
| Q1 25 | $-25.7M | $-8.0M | ||
| Q4 24 | $27.8M | $7.0M | ||
| Q3 24 | $35.9M | $-1.1M | ||
| Q2 24 | $12.9M | $-10.6M | ||
| Q1 24 | $18.6M | $-4.7M |
自由现金流率LGNDRDI
| Q4 25 | 76.9% | 8.2% | ||
| Q3 25 | 11.3% | -0.5% | ||
| Q2 25 | 32.7% | 1.9% | ||
| Q1 25 | -56.6% | -19.8% | ||
| Q4 24 | 64.8% | 12.0% | ||
| Q3 24 | 69.4% | -1.8% | ||
| Q2 24 | 31.1% | -22.7% | ||
| Q1 24 | 60.1% | -10.4% |
资本支出强度LGNDRDI
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.4% | 0.6% | ||
| Q1 25 | 0.5% | 0.6% | ||
| Q4 24 | 1.7% | 1.7% | ||
| Q3 24 | 1.2% | 4.0% | ||
| Q2 24 | 1.0% | 0.5% | ||
| Q1 24 | 0.3% | 4.3% |
现金转化率LGNDRDI
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 3.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGND
| Intangible Royalty Assets | $40.7M | 68% |
| Financial Royalty Assets | $9.8M | 16% |
| Material Sales Captisol | $7.8M | 13% |
| Vaxneuvance | $1.4M | 2% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
